Novo Nordisk CEO: Semaglutide could create serious obesity treatment market

Come summer, Novo Nordisk will know whether semaglutide can be used as obesity treatment, and CEO Lars Fruergaard Jørgensen says this approval has potential to change the market for obesity treatment.
Photo: Valdemar Ren
Photo: Valdemar Ren
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN

Novo Nordisk has great expectations for the potential launch of its drug, semaglutide, to treat severe obesity.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading